TY - JOUR
T1 - BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
AU - Dawson, Sarah-Jane
AU - Makretsov, Nikitsa
AU - Blows, Fiona
AU - Driver, Kristy
AU - Provenzano, Elena
AU - Le Quesne, John
AU - Baglietto, Laura
AU - Severi, Gianluca
AU - Giles, Graham
AU - McLean, Catriona Ann
AU - Callagy, Grace
AU - Green, Andrew
AU - Ellis, Ian
AU - Gelmon, Karen
AU - Turashvili, Gulisa
AU - Leung, S
AU - Aparcio, S
AU - Huntsman, David
AU - Caldas, Carlos
AU - Pharoah, Paul
PY - 2010
Y1 - 2010
N2 - Five studies of 11 212 women with early-stage breast cancer were analysed. Individual patient data included tumour size,
grade, lymph node status, endocrine therapy, chemotherapy and mortality. BCL2, ER, progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) levels were determined in all tumours. A Cox model incorporating the
time-dependent effects of each variable was used to explore the prognostic significance of BCL2.
AB - Five studies of 11 212 women with early-stage breast cancer were analysed. Individual patient data included tumour size,
grade, lymph node status, endocrine therapy, chemotherapy and mortality. BCL2, ER, progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) levels were determined in all tumours. A Cox model incorporating the
time-dependent effects of each variable was used to explore the prognostic significance of BCL2.
UR - http://www.nature.com/bjc/journal/v103/n5/pdf/6605736a.pdf
U2 - 10.1038/sj.bjc.6605736
DO - 10.1038/sj.bjc.6605736
M3 - Article
VL - 103
SP - 668
EP - 675
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 5
ER -
